StreetAlpha
13F holdings · Q3 2026

Logos Global Management

San Francisco, CA · files as Logos Global Management LP
Know the moment Logos Global Management filesYou follow Logos Global Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1792126

Logos Global Management reported 59 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (7.5%), RVMD (7.4%) and IDYA (6.6%). Compared with Q2 2026, the fund opened new positions in MDGL, NBIX and AXSM, added to PRAX, IRON and ELVN, trimmed RVMD, IDYA and ERAS and sold out of CLDX, CMPS and MLYS.

Latest filing: what Logos Global Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
16 new10 added24 trimmed25 sold outBought about $401M · sold about $828M
New 16
See all 16 →
Added 10
See all 10 →
Trimmed 24
See all 24 →
Sold out 25
See all 25 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.7B−28.8% vs last quarter · $1.9B including options
Stocks held5916 new · 25 sold out
Top 5 weight32.0%spread out
Turnover74%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PRAX
Praxis Precision Medicines I
$124M7.5%425K+165K (+63%)6 of 8
2
RVMD
Revolution Medicines Inc
$123M7.4%600K−100K (−14%)8 of 8
3
IDYA
Ideaya Biosciences Inc
$109M6.6%2.9M−150K (−5%)8 of 8
4
ERAS
Erasca Inc
$86.5M5.2%5.9M−6.3M (−51%)8 of 8
5
ABVX
Abivax SA
$86.1M5.2%870K−154K (−15%)5 of 8
6
CGON
CG Oncology Inc
$69.1M4.2%975K−25K (−3%)4 of 8
7
IRON
Disc Medicine Inc
$66.4M4.0%1M+140K (+16%)8 of 8
8
BNTX
Biontech SE
$63.9M3.9%650K−365K (−36%)4 of 8
9
TNGX
Tango Therapeutics Inc
$53.6M3.2%2.1M−700K (−25%)5 of 8
10
MDGL
Madrigal Pharmaceuticals Inc
$50.4M3.0%100KNew position3 of 8
🔒 49 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
CLDX
Celldex Therapeutics Inc
$78.1M2.1M
CMPS
Compass Pathways PLC
$31.8M2.3M
MLYS
Mineralys Therapeutics Inc
$28.3M1.1M
REPL
Replimune Group Inc
$27.7M2.5M
XENE
Xenon Pharmaceuticals Inc
$27.2M450K

🔒 Free account: see all 25.

Options

valued at the underlying shares
StockTypeValueSharesChange
ERAS
Erasca Inc
Call$36.6M2.5M+2,500,000
AVTX
Avalo Therapeutics Inc
Call$23M1.5M+1,500,000
REPL
Replimune Group Inc
Call$19.9M1.5M+1,500,000
DSGN
Design Therapeutics Inc
Call$18.9M1.5M+1,500,000
SRPT
Sarepta Therapeutics Inc
Call$18.2M1M+1,000,000

🔒 Free account: see all 13.

Reported value

last 8 quarters
$855MQ4 '24
$563MQ1 '25
$749MQ2 '25
$1BQ3 '25
$1.5BQ4 '25
$1.9BQ1 '26
$2.3BQ2 '26
$1.7BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Logos Global Management 13F FAQ

What does Logos Global Management own?

Logos Global Management reported 59 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (7.5%), RVMD (7.4%) and IDYA (6.6%). The table above lists every position in the filing (the top 10 without an account).

What did Logos Global Management buy and sell in Q3 2026?

Compared with Q2 2026: 16 new positions, 10 added to, 24 trimmed and 25 sold out. New positions include MDGL, NBIX and AXSM. It sold all of CLDX, CMPS and MLYS.

When will Logos Global Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Logos Global Management's portfolio worth?

The Q3 2026 filing reports $1.7B in US stocks ($1.9B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.